Danne, T., Nimri, R., Battelino, T., Bergenstal, R.M., Close, K.L., DeVries, J.H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S.A., Beck, R., Bosi, E., Buckingham, B., Cobelli, C., Dassau, E., Doyle, F. J., Heller, S., Hovorka, R., Jia, W., Phillip, M., et al. (2017) International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 40, 1631-1640.
https://doi.org/10.2337/dc17-1600

has been cited by the following article:

• TITLE: The Use of Standardized Reporting and Time-in-Range in the Management of Diabetes: A Consensus Report

  AUTHORS: Saud Al Sifri, Adnan Alshaikh, Bassam Bin-Abbas, Eman Sheshah, Fahad Al Sabaan, Mohammed Al-Dawish, Mohammed Al-Dubayee, Naweed Al-Zaman, Raed A. Al-Dahash, Saad Alzahrani, Emad R. Issak

  KEYWORDS: Diabetes, Time in Range, Glycemic Control, HbA1c

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.12 No.8, August 5, 2021

  ABSTRACT: Introduction: The exhaustion of healthcare resources due to the rising prevalence in Saudi Arabia mandates the search for each method that can help in better control of diabetes. Methods: The gathered task force gath-ered to develop an explicit, evidence-based consensus for the use of time-in-range targets as guidance for better glycemic control while using continuous glucose monitoring (CGM). This article has the recommenda-tions of this expert panel. Results: HbA1c and self-monitoring blood glu-cose (SMBG) are not enough to detect blood glucose (BG) fluctuations on a daily basis. The incorporation of technology like FreeStyle Libre with its applications like Libre View is now used in many institutes in Saudi Ara-bia. This system is comprehensive and has all the standardized metrics needed. However, training and support are always needed. Barriers and challenges include the awareness & experience of the technology, the time barrier, the patients’ barriers, the technical barriers, and of course, the availability barrier. All the barriers and challenges should be dealt with by designing new training programs. Conclusion: The expert panel recom-mended using CGMs technology in people with type 1 diabetes (T1DM) children and adults, type 2 diabetes (T2DM) on multiple insulin injections, gestational diabetes (GDM) who need further glycemic control, and those at high risk for hypoglycemia. In addition, we recommend using them for a short period for those who require intensive BG control or during acute illness or stress. In addition, Ambulatory Glucose Profile (AGP) could be used as an educational tool for any individuals with DM to study the im-pact of certain elements of lifestyle modifications on their immediate BG level.